Review article · 2025 · Open access

Fluid biomarkers for neurodegenerative diseases: a comprehensive update

Martina Valletta, Nils Briel, Idil Yuksekel, Michelle C. Barboure, A. R. Coward, Julie F. H. De Houwer, Ayesha Fawad, Alberto González-Mayoral, Gianmarco Iaccarino, Francisco Martínez‐Dubarbie, Shirine Moukaled, Ulf Andréasson and 10 more

Alzheimer s Research & Therapy, 18(1), 12 · Published 20 December 2025 · DOI 10.1186/s13195-025-01919-z

Open full textCite this paper

In brief

“Fluid biomarkers for neurodegenerative diseases: a comprehensive update” is a 2025 review article by Martina Valletta and 21 co-authors, published in Alzheimer s Research & Therapy. OpenAlex counts 26 citations as of 18 November 2026, which puts it in the top 1% of works published in 2025 by citations. It is open access under a CC BY licence: the full text is free to read at Alzheimer s Research & Therapy.

Citations
26
Most cited in
2026 (26)
Field-weighted impact
2.08
References
176
Authors
22

Abstract

Fluid biomarkers are revolutionizing the diagnosis and management of neurodegenerative diseases by enabling earlier diagnosis and disease monitoring. In particular, blood-based biomarkers have emerged as a minimally invasive and scalable alternative to cerebrospinal fluid analysis. Recent advances in blood-based tau biomarkers have shown high diagnostic accuracy for Alzheimer’s disease (AD). Other neurodegenerative diseases—such as synucleinopathies, frontotemporal lobar degeneration, limbic-predominant age-related TDP-43 encephalopathy (LATE), and amyotrophic lateral sclerosis—pose substantial challenges due to their heterogeneous clinical presentations and the current absence of robust biomarkers for hallmark pathologies. Nonetheless, promising candidate markers are emerging for improved disease characterization and staging. Technological innovations, including single-molecule arrays (Simoa), advanced mass spectrometry workflows and nucleic acid linked immune-sandwich assay (NULISA) have markedly enhanced the sensitivity and precision of biomarker quantification from low-concentration biological matrices. More recently, the development of fully automated platforms shows great promise for routine measurement of blood-based biomarkers in clinical settings. Despite this progress key challenges remain, including the need for improved assay reproducibility, standardization, and the optimization of clinical workflows. In this review, we provide a comprehensive update on recent progress in fluid biomarker research across AD and major neurodegenerative diseases, highlight technological advances in detection methods, and discuss current challenges and opportunities for clinical translation.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Valletta, M., Briel, N., Yuksekel, I., Barboure, M. C., Coward, A. R., De Houwer, J. F. H., Fawad, A., González-Mayoral, A., Iaccarino, G., Martínez‐Dubarbie, F., Moukaled, S., Andréasson, U., Gobom, J., Brinkmalm, A., Tijms, B. M., Zetterberg, H., Blennow, K., Suárez‐Calvet, M., Schöll, M., . . . Sogorb‐Esteve, A. (2025). Fluid biomarkers for neurodegenerative diseases: a comprehensive update. Alzheimer s Research & Therapy, 18(1), 12. https://doi.org/10.1186/s13195-025-01919-z

MLA 9

Valletta, Martina, et al. “Fluid biomarkers for neurodegenerative diseases: a comprehensive update.” Alzheimer s Research & Therapy, vol. 18, no. 1, 2025, p. 12. https://doi.org/10.1186/s13195-025-01919-z.

Chicago

Valletta, Martina, Nils Briel, Idil Yuksekel, Michelle C. Barboure, A. R. Coward, Julie F. H. De Houwer, Ayesha Fawad, et al. 2025. “Fluid biomarkers for neurodegenerative diseases: a comprehensive update.” Alzheimer s Research & Therapy 18 (1): 12. https://doi.org/10.1186/s13195-025-01919-z.

Harvard

Valletta, M. et al. (2025) ‘Fluid biomarkers for neurodegenerative diseases: a comprehensive update’, Alzheimer s Research & Therapy, 18(1), p. 12. doi:10.1186/s13195-025-01919-z.

IEEE

M. Valletta et al., “Fluid biomarkers for neurodegenerative diseases: a comprehensive update,” Alzheimer s Research & Therapy, vol. 18, no. 1, p. 12, 2025, doi: 10.1186/s13195-025-01919-z.

BibTeX

@article{valletta2025fluid,
  title     = {{Fluid biomarkers for neurodegenerative diseases: a comprehensive update}},
  author    = {Valletta, Martina and Briel, Nils and Yuksekel, Idil and Barboure, Michelle C. and Coward, A. R. and De Houwer, Julie F. H. and Fawad, Ayesha and González-Mayoral, Alberto and Iaccarino, Gianmarco and Martínez‐Dubarbie, Francisco and Moukaled, Shirine and Andréasson, Ulf and Gobom, Johan and Brinkmalm, Ann and Tijms, Betty Marije and Zetterberg, Henrik and Blennow, Kaj and Suárez‐Calvet, Marc and Schöll, Michael and Paterson, Ross W. and Montoliu‐Gaya, Laia and Sogorb‐Esteve, Aitana},
  journal   = {Alzheimer s Research \& Therapy},
  year      = {2025},
  volume    = {18},
  number    = {1},
  pages     = {12},
  doi       = {10.1186/s13195-025-01919-z},
  url       = {https://doi.org/10.1186/s13195-025-01919-z}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments

  • fluid biomarkers
  • blood-based biomarkers
  • neurodegenerative diseases
  • Alzheimer's disease
  • tau biomarkers
  • synucleinopathies
  • frontotemporal lobar degeneration
  • limbic-predominant age-related TDP-43 encephalopathy

Work with this paper

Most-cited papers in Neuroscience

All highly cited Neuroscience papers

Questions about this paper

How do I cite this paper in APA style?

Valletta, M., Briel, N., Yuksekel, I., Barboure, M. C., Coward, A. R., De Houwer, J. F. H., Fawad, A., González-Mayoral, A., Iaccarino, G., Martínez‐Dubarbie, F., Moukaled, S., Andréasson, U., Gobom, J., Brinkmalm, A., Tijms, B. M., Zetterberg, H., Blennow, K., Suárez‐Calvet, M., Schöll, M., . . . Sogorb‐Esteve, A. (2025). Fluid biomarkers for neurodegenerative diseases: a comprehensive update. Alzheimer s Research & Therapy, 18(1), 12. https://doi.org/10.1186/s13195-025-01919-z

How many times has this paper been cited?

26 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Alzheimer s Research & Therapy: sign in and open the full text from this page.

Who wrote this paper?

Martina Valletta, Nils Briel, Idil Yuksekel, Michelle C. Barboure, A. R. Coward, Julie F. H. De Houwer, Ayesha Fawad, Alberto González-Mayoral, Gianmarco Iaccarino, Francisco Martínez‐Dubarbie, Shirine Moukaled, Ulf Andréasson and 10 more.

What is the DOI of this paper?

10.1186/s13195-025-01919-z, permanently at https://doi.org/10.1186/s13195-025-01919-z. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.